Skip to main content

BUSQUEDA DE REMIELINIZACION EFECTIVA PARA LA ESCLEROSIS MULTIPLE

PID2019-109858RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Myeloid-derived suppressor cells support remyelination in a murine model of Multiple Sclerosis by promoting oligodendrocyte precursor cell survival, proliferation and differentiation

  • Melero-Jerez, Carolina
  • Fernández-Gómez, Beatriz
  • Lebrón-Galán, Rafael
  • Ortega, María C.
  • Sánchez-de Lara, I.
  • Ojalvo-Sanz, Ana Cristina
  • Clemente, Diego
  • Castro Soubriet, Fernando de
The most frequent variant of multiple sclerosis (MS) is the relapsing-remitting form, characterized by symptomatic phases followed by periods of total/partial recovery. Hence, it is possible that these patients can benefit from endogenous agents that control the inflammatory process and favor spontaneous remyelination. In this context, there is increasing interest in the role of myeloid-derived suppressor cells (MDSCs) during the clinical course of experimental autoimmune encephalomyelitis (EAE). MDSCs speed up infiltrated T-cell anergy and apoptosis. In different animal models of MS, a milder disease course is related to higher presence/density of MDSCs in the periphery, and smaller demyelinated lesions in the central nervous system (CNS). These observations lead us to wonder whether MDSCs might not only exert an anti-inflammatory effect but might also have direct influence on oligodendrocyte precursor cells (OPCs) and remyelination. In the present work, we reveal for the first time the relationship between OPCs and MDSCs in EAE, relationship that is guided by the distance from the inflammatory core. We describe the effects of MDSCs on survival, proliferation, as well as potent promoters of OPC differentiation toward mature phenotypes. We show for the first time that osteopontin is remarkably present in the analyzed secretome of MDSCs. The ablation of this cue from MDSCs-secretome demonstrates that osteopontin is the main MDSC effector on these oligodendroglial cells. These data highlight a crucial pathogenic interaction between innate immunity and the CNS, opening ways to develop MDSC- and/or osteopontin-based therapies to promote effective myelin preservation and repair in MS patients., This work was supported by the Spanish Ministerio de Economía, Industria y Competitividad-MINEICO (currently Ministerio de Ciencia e Innovación: grants SAF2012-40023, SAF2015-72325-EXP, SAF2016-77575-R, and PID2019-109858RB-I00); the Instituto de Salud Carlos III (grants RD12-0032-12, RD16-0015-0019, PI15-00963, and PI18-00357—partially financed by F.E.D.E.R.: European Union “Una manera de hacer Europa”-); the Spanish Research Council/Consejo Superior de Investigaciones Científicas-CSIC (grants CSIC-2015201023, 2019AEP033, and LINKA20268); and ADEM-TO (Spain), ATORDEM (Spain), AELEM (Spain), and ARSEP Foundations (France). D. C. and R. L. G. were financed by SESCAM. C. M.-J. held a BES-2013-062630 predoctoral Research Training contract from MINEICO (associated with SAF2012-40023 and PI15-00963) and a contract under SAF2015-72325-EXP and SAF2016-77575-R. B. F.-G. is currently contracted under IND2018/BMD-9751 (Comunidad de Madrid, Spain). M. C. O holds a postdoctoral contract from the Consejería de Sanidad de Castilla-La Mancha (II-2018_07). Dr Clemente's group was sponsored by Aciturri Aeronáutica SLA, Fundación Galletas Coral, and Embutidos y Jamones España e Hijos.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinson’s disease

  • Villadiego, Javier
  • García-Swinburn, Roberto
  • García-González, Diego
  • Lebrón-Galán, Rafael
  • Murcia-Belmonte, Verónica
  • García-Roldán, Ernesto
  • Suárez-Luna, Nela
  • Nombela, Cristina
  • Marchena, Miguel A.
  • Castro Soubriet, Fernando de
  • Toledo-Aral, Juan José
The development and survival of dopaminergic neurons are influenced by the fibroblast growth factor (FGF) pathway. Anosmin-1 (A1) is an extracellular matrix protein that acts as a major regulator of this signaling pathway, controlling FGF diffusion, and receptor interaction and shuttling. In particular, previous work showed that A1 overexpression results in more dopaminergic neurons in the olfactory bulb. Prompted by those intriguing results, in this study, we investigated the effects of A1 overexpression on different populations of catecholaminergic neurons in the central (CNS) and the peripheral nervous systems (PNS). We found that A1 overexpression increases the number of dopaminergic substantia nigra pars compacta (SNpc) neurons and alters the striosome/matrix organization of the striatum. Interestingly, these numerical and morphological changes in the nigrostriatal pathway of A1-mice did not confer an altered susceptibility to experimental MPTP-parkinsonism with respect to wild-type controls. Moreover, the study of the effects of A1 overexpression was extended to different dopaminergic tissues associated with the PNS, detecting a significant reduction in the number of dopaminergic chemosensitive carotid body glomus cells in A1-mice. Overall, our work shows that A1 regulates the development and survival of dopaminergic neurons in different nuclei of the mammalian nervous system., This research was supported by MCIN/Spanish Research Agency (AEI)/grants PID2019-105995RB-I00 (J.J.T.-A. and J.V.) and PID2019-109858RB-I00 (to F. dC.); ISCIII grants Red TerCel, RD16/0011/0025 (J.J.T.-A.), PI12/02574 (J.J.T.-A.), CP21/00106 (DG-G) and PI22/00156 (DG-G); Consejería de Innovación, Ciencia y Empresa grant CTS2739 (J.J.T.-A.), Consejería de Economía, Conocimiento, Empresas y Universidad grant US-1380891 (J.J.T.-A. and J.V.), Junta de Andalucía., Funding for open access publishing: Universidad de Sevilla/CBUA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis

  • Benítez-Fernández, Rocío
  • Josa-Prado, Fernando
  • Sánchez, Estefanía
  • Lao, Yolanda
  • García-Rubia, Alfonso
  • Cumella, José
  • Martínez, Ana
  • Palomo, Valle
  • Castro Soubriet, Fernando de
Multiple sclerosis (MS) is a chronic neurological disease that currently lacks effective curative treatments. There is a need to find effective therapies, especially to reverse the progressive demyelination and neuronal damage. Oligodendrocytes form the myelin sheath around axons in the central nervous system (CNS) and oligodendrocyte precursor cells (OPCs) undergo mechanisms that enable spontaneously the partial repair of damaged lesions. The aim of this study was to discover small molecules with potential effects in demyelinating diseases, including (re)myelinating properties., Comunidad de Madrid, Grant/Award Number: PEJ-2019-TL/BMD-1426; Consejo Superior de Investigaciones Científicas, Grant/Award Number: 2023AEP096; Fundación Ramón Areces, Grant/Award Number: CIVP19A5917; Ministerio de Ciencia e Innovación, Grant/ Award Number: PID2019-109858RB-I00, PID2022-143110OB-I00 and RYC2019- 027489-I, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activation of Shh/Smo is sufficient to maintain oligodendrocyte precursor cells in an undifferentiated state and is not necessary for myelin formation and (re)myelination.

  • Nocera, Sonia
  • Marchena, Miguel A.
  • Fernández-Gómez, Beatriz
  • Gómez-Martín, Paula
  • Sánchez-Jiménez, Estefanía
  • Macías-Castellano, A.
  • Lao, Yolanda
  • Cordano, C.
  • Gómez-Torres, Óscar
  • Luján, Rafael
  • Castro Soubriet, Fernando de
Myelination is the terminal step in a complex and precisely timed program that orchestrates the proliferation, migration and differentiation of oligodendroglial cells. It is thought that Sonic Hedgehog (Shh) acting on Smoothened (Smo) participates in regulating this process, but that these effects are highly context dependent. Here, we investigate oligodendroglial development and remyelination from three specific transgenic lines: NG2-CreERT2 (control), Smofl/fl/NG2-CreERT2 (loss of function), and SmoM2/NG2-CreERT2 (gain of function), as well as pharmacological manipulation that enhance or inhibit the Smo pathway (Smoothened Agonist (SAG) or cyclopamine treatment, respectively). To explore the effects of Shh/Smo on differentiation and myelination in vivo, we developed a highly quantifiable model by transplanting oligodendrocyte precursor cells (OPCs) in the retina. We find that myelination is greatly enhanced upon cyclopamine treatment and hypothesize that Shh/Smo could promote OPC proliferation to subsequently inhibit differentiation. Consistent with this hypothesis, we find that the genetic activation of Smo significantly increased numbers of OPCs and decreased oligodendrocyte differentiation when we examined the corpus callosum during development and after cuprizone demyelination and remyelination. However, upon loss of function with the conditional ablation of Smo, myelination in the same scenarios are unchanged. Taken together, our present findings suggest that the Shh pathway is sufficient to maintain OPCs in an undifferentiated state, but is not necessary for myelination and remyelination., This research was supported by the Spanish Ministerio de Ciencia e Investigación-MCIN/Spanish Research Agency-AEI (grants SAF2012-400232, SAF2016-77575-R, RD12-0032/0012, RD16-0015/0019,PID2019-109858RB-I00, EIN2020-112366, and PID2022-143110OB-I00-MCIN/AEI/10.13039/501100011033/-), CSIC/Spanish ResearchCouncil (grants BDC-20213231 and 2023AEP096), and FundaciónRamón Areces (Spain; grant CIVP19A5917), and a grant from Proyectosde Investigación Relacionados con las Enfermedades Raras Infantiles from Fundación Inocente Inocente (Spain), all to F. dC. SN had a predoctoral contract of the Universidad de Castilla-La Mancha, and then was hired under grant IND2018/BMD-9751 (Comunidad de Madrid, Spain) to F.dC. BF-G was predoctoral researcher contracted under IND2018/BMD-9751 (Programa de Doctorados Industriales de la Comunidad de Madrid, Spain), to F.dC. YL was hired under grants from Spanish Ministerio de Ciencia e Investigación-MCIN/Spanish Research Agency-AEIRD16/0015/0019 and PID2019-109858RB-I00. PG-M is currently hired under PID2022-143110OB-I00. We are deeply in debt with Mrs.Laudelina Garmendia for her unvaluable help in the Animal Facilities of the Instituto Cajal: she did almost miracles during pandemics to keep alive mice colonies in numbers enough to allow fast restarting of experiments once de confined. Finally, we would like to thank Dr. Javier Mazarío (Hospital Nacional de Parapléjicos, Toledo, Spain) for his invaluable help in the confocal microscopy and quantification advice
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Herpes Simplex Virus type 1 inhibits autophagy in glial cells but requires ATG5 for the success of viral replication.

  • Ripa, Inés
  • Andreu, Sabina
  • Fernández-Gómez, Beatriz
  • Josa-Prado, Fernando
  • Castro Soubriet, Fernando de
  • Arribas, María
  • Bello-Morales, Raquel
  • López-Guerrero, José Antonio
Herpes Simplex Virus type 1 (HSV-1) 1 is a neurotropic virus that has been associated with neurodegenerative disorders. The dysregulation of autophagy by HSV-1 has been proposed as a potential cause of neurodegeneration. While studies have extensively tackled the interaction between autophagy and HSV-1 in neurons, research in glial cells is currently limited. Our studies demonstrate that HSV-1 inhibits, but not completely blocks, the formation of autophagosomes in human oligodendroglioma- and astrocytoma- derived cell lines. These findings have been confirmed in murine oligodendrocyte precursor cells (OPCs). Finally, this study investigates the impact of autophagy on HSV-1 infection in glial cells. While the lack of basal autophagy in LC3B knockout glial cells does not have a significant effect on viral infection, cells without the autophagy-related protein ATG5 exhibit reduced viral production. The absence of ATG5 leads to a decrease in the transcription and replication of viral genes, as well as a delay in the initial stages of the formation of HSV-1 replication compartments. These findings indicate that while autophagy may not play a significant role in antiviral defense in glial cells, HSV-1 may be inhibiting autophagy to exploit non-canonical functions of certain components of the autophagic machinery, such as ATG5, to benefit its lifecycle., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by Ministerio de Ciencia e Innovación, Spain (grants number PID2019-110570GB-I00 to JL-G and PID2019-109858RB-I00 and PID2022-143110OB-I00 (funded by MCIN/AEI/ 10.13039/501100011033) to FC). BF-G was predoctoral researcher contracted under IND2018/BMD-9751 (Programa de Doctorados Industriales de la Comunidad de Madrid, Spain), to FC. FJ-P was hired under grant CIVP19A5917 from Fundación Ramón Areces (Spain) to FC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis

  • Fernández-Gómez, Beatriz
  • Marchena, Miguel A
  • Piñeiro, David
  • Gómez-Martín, Paula
  • Sánchez, Estefanía
  • Laó, Yolanda
  • Valencia, Gloria
  • Nocera, Sonia
  • Benítez-Fernández, Rocío
  • Castaño-León, Ana M
  • Lagares, Alfonso
  • Hernández-Jiménez, Macarena
  • Castro Soubriet, Fernando de
ApTOLL is an aptamer selected to antagonize toll-like receptor 4 (TLR4), a relevant actor for innate immunity involved in inflammatory responses in multiple sclerosis (MS) and other diseases. The currently available therapeutic arsenal to treat MS is composed of immunomodulators but, to date, there are no (re)myelinating drugs available in clinics. In our present study, we studied the effect of ApTOLL on different animal models of MS., This work was supported by the following grants and contractsto FdC: IND2018/BMD-9751 (Programa de Doctorados Industriales,Comunidad de Madrid, Spain); SAF2016-77575-R, PID2019-109858RB-I00, PID2022-143110OB-I00, EIN2020-112366 and RD16/0015/0019 (grant funded by the Spanish Ministerio de Ciencia Investigación e Innovación—MCIN/AEI/10.13039/501100011033and by ‘ERDF a way of making Europe’ by the European Union), 2019AEP033 (from Consejo Superior de Investigaciones Científicas—CSIC, Spain), and a contract for technological support (20184174) from Apta Targets SL (Spain). BF-G is currently hired by Apta Targets SL; PG-M was contracted as Ayudante de Investigación (PEJ-2020-AI/BMD-18541), associated with the Fondo de Garantía Juvenil (call 2020), financed by Comunidad de Madrid (Spain) and now hired under Grant 2019AEP033; SN was hired under IND2018/BMD-9751 (to FdC); and YL has been contracted under RD16/0015/0019 andPID2019-109858RB-I00. We thank David Segarra and Mª Eugenia Zarabozo (AptaTargets SL) for their constant technological support,Laude Garmendia for her indispensable constant help at the animal facility (Instituto Cajal—CSIC), including the extra effort during COVID-19 pandemics, and Dr. Carolina Melero-Jerez (a former mem-ber of the FdC research group, currently working at Jazz Pharma,Spain) for the initial training of BF-G on the EAE animal model and dif-ferent techniques at the laboratory., Peer reviewed